You are here: Home » International » News » Others
Business Standard

Vaccines effective against severe disease, hospitalisation by Omicron: EMA

Citing preliminary data, the European Medicines Agency (EMA) has said that the Covid-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron coronavirus variant.

Topics
Coronavirus Vaccine | Coronavirus | Omicron

IANS  |  Brussels 

Covid vaccine

Citing preliminary data, the European Medicines Agency (EMA) has said that the Covid-19 vaccines remain effective against severe disease and hospitalisation caused by the variant.

"Although appears to be more infectious than other variants, studies conducted in South Africa, the UK and some European Union (EU) member states show a lower risk of being hospitalised after infection with Based on these studies, the risk is currently estimated to be between a third and half of the risk with the Delta variant," the EMA said on Tuesday in a release.

It cited results from recently published studies as showing that vaccine effectiveness against symptomatic disease is lower for Omicron than for other variants and tends to wane over time. As a result, more vaccinated people are likely to develop breakthrough disease due to Omicron.

However, these studies also show that vaccination continues to provide a high level of protection against severe disease and hospitalisation linked to the Omicron variant, Xinhua news agency reported.

The latest evidence, which includes real-world effectiveness data, also suggests that people who have had a booster dose are better protected than those who have only received their primary course.

The EMA's Head of Vaccines Strategy, Marco Cavaleri, said at a press conference on Tuesday that the agency continued to monitor the vaccines' effectiveness, and the outcome of this assessment may impact future vaccination strategies recommended by experts in the EU member states.

He added that having to take a booster dose every three or four months was not effective enough as a long-term strategy.

"We do not yet have data on the fourth dose to allow us to express ourselves, but we are concerned about a strategy that foresees going ahead with vaccinations in a short time," he said.

The EMA added in the statement that efforts should continue to increase full vaccination uptake in individuals who are currently unvaccinated or partially vaccinated and to accelerate the rollout of booster doses.

--IANS

int/khz/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 12 2022. 07:45 IST
RECOMMENDED FOR YOU
.